Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics

第二代多核铂化合物。

• 批准号: DP0662817
• 负责人: Prof Susan Berners-Price
• 金额: $ 18.72万
• 依托单位: The University of Western Australia
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-03-03 至 2009-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0662817
• 关键词: Second; Generation; Polynuclear; Platinum; Compounds.

Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students.

四分之一的澳大利亚人患有癌症，50%的癌症患者接受顺铂治疗。BBR3464是一种新型的铂类抗癌药物，已在临床试验中显示出前景，包括对顺铂治疗无效的癌症的结果。目前正在开发的第二代类似物可能会提供显著的优势。伯纳斯-普莱斯教授和这些新药的发明者之间的这种国际合作使澳大利亚的研究处于临床开发的前沿。在改进的抗癌药物设计中，有可能从新的策略中产生新的知识产权。该项目建立了强大的国际联系，并为澳大利亚博士生提供国际培训。